PillRx only · Spray · Nasal
Dihydroergotamine Mesylate
Dihydroergotamine Mesylate
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$36.168
Latest avg · Jul 22, 2026
+12%
Since Dec 17, 2025
3
Active US suppliers
75%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
864
Rx · 2026 Q1
6.6K
Units dispensed
-39%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 1 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Advagen Pharma Ltd | unknown | 2 | SUPPLYING |
| Trifluent Pharma LLC | unknown | 1 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | unknown | 1 | SUPPLYING |
| Oceanside Pharmaceuticals | unknown | 1 | EXITED 2027 |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.